Biosimilar versions of Epogen (Epoetin Alfa) may be launched as early as 2013. This launch is expected to be followed by launches of biosimilar versions of Neupogen (Filgrastim) and Neulasta (Pegfilgrastim).
By : |
11-17-2011
|
Business:Markets
| Total Views :
772